Jump to content

Brefonalol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 12:47, 20 July 2021 (Some context). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Brefonalol
Names
IUPAC name
6-[1-Hydroxy-2-[(2-methyl-4-phenylbutan-2-yl)amino]ethyl]-3,4-dihydro-1H-quinolin-2-one
Other names
Brefanolol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C22H28N2O2/c1-22(2,13-12-16-6-4-3-5-7-16)23-15-20(25)18-8-10-19-17(14-18)9-11-21(26)24-19/h3-8,10,14,20,23,25H,9,11-13,15H2,1-2H3,(H,24,26)
    Key: YYUZPBGIBVJYSI-UHFFFAOYSA-N
  • InChI=1/C22H28N2O2/c1-22(2,13-12-16-6-4-3-5-7-16)23-15-20(25)18-8-10-19-17(14-18)9-11-21(26)24-19/h3-8,10,14,20,23,25H,9,11-13,15H2,1-2H3,(H,24,26)
    Key: YYUZPBGIBVJYSI-UHFFFAOYAN
  • CC(C)(CCC1=CC=CC=C1)NCC(C2=CC3=C(C=C2)NC(=O)CC3)O
Properties
C22H28N2O2
Molar mass 352.478 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Brefonalol is a beta-adrenergic antagonist that reduces heart frequency and blood pressure and dilates blood vessels. It has been studied in around 1990,[1] but is not known to be marketed as of 2021.

References

  1. ^ Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension". Journal of Cardiovascular Pharmacology. 16 (1): 81–6. doi:10.1097/00005344-199007000-00011. PMID 1696669. S2CID 41692901.